Fayez Sarofim & CO Novo Nordisk A S Transaction History

Fayez Sarofim & CO

$33 Billion
Q1 2024

A detailed history of Fayez Sarofim & CO transactions in Novo Nordisk A S stock. As of the latest transaction made, Fayez Sarofim & CO holds 11,815,837 shares of NVO stock, worth $1.6 Billion. This represents 4.6% of its overall portfolio holdings.

Number of Shares

11,815,837

Previous 11,814,051 0.02%

Holding current value

$1.6 Billion

Previous $1.22 Billion 24.14%

% of portfolio

4.6%

Previous 3.94%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$102.11 - $135.92 $182,368 - $242,753	1,786 Added 0.02%	11,815,837 $1.52 Billion
Q4 2023 Feb 14, 2024	BUY	$87.78 - $105.45 $18.4 Million - $22.2 Million	210,087 Added 1.81%	11,814,051 $1.22 Billion
Q3 2023 Nov 14, 2023	BUY	$90.94 - $199.54 $590 Million - $1.29 Billion	6,484,279 Added 126.65%	11,603,964 $1.06 Billion
Q2 2023 Aug 14, 2023	SELL	$155.98 - $172.65 $25.1 Million - $27.7 Million	-160,672 Reduced 3.04%	5,119,685 $829 Million
Q1 2023 May 11, 2023	BUY	$132.34 - $159.14 $21.7 Million - $26.1 Million	163,988 Added 3.21%	5,280,357 $840 Million

Q4 2022 Feb 13, 2023	SELL	$102.55 - $135.33 $10.4 Million - $13.8 Million	-101,735 Reduced 1.95%	5,116,369 $692 Million
Q3 2022 Nov 14, 2022	BUY	$95.28 - $116.93 $42.9 Million - $52.7 Million	450,280 Added 9.44%	5,218,104 $520 Million
Q2 2022 Aug 12, 2022	BUY	$103.24 - $121.81 $68,241 - $80,516	661 Added 0.01%	4,767,824 $531 Million
Q1 2022 May 16, 2022	SELL	$93.1 - $112.54 $6.05 Million - $7.32 Million	-65,017 Reduced 1.35%	4,767,163 $529 Million
Q4 2021 Feb 11, 2022	SELL	$95.88 - $117.08 $8.64 Million - $10.5 Million	-90,094 Reduced 1.83%	4,832,180 $541 Million
Q3 2021 Nov 15, 2021	SELL	$84.42 - $106.62 $724,998 - $915,652	-8,588 Reduced 0.17%	4,922,274 $473 Million
Q2 2021 Aug 13, 2021	SELL	$67.66 - $84.76 $2.33 Million - $2.92 Million	-34,493 Reduced 0.69%	4,930,862 $413 Million
Q1 2021 May 13, 2021	SELL	$67.06 - $75.82 $1.21 Million - $1.37 Million	-18,092 Reduced 0.36%	4,965,355 $335 Million
Q4 2020 Feb 11, 2021	SELL	$63.89 - $73.8 $1.07 Million - $1.23 Million	-16,730 Reduced 0.33%	4,983,447 $348 Million
Q3 2020 Nov 13, 2020	SELL	$63.69 - $70.22 $4 Million - $4.41 Million	-62,870 Reduced 1.24%	5,000,177 $347 Million
Q2 2020 Aug 11, 2020	BUY	$58.54 - $67.94 $49.1 Million - $56.9 Million	838,111 Added 19.84%	5,063,047 $332 Million
Q1 2020 May 12, 2020	SELL	$49.46 - $64.78 $8.89 Million - $11.6 Million	-179,664 Reduced 4.08%	4,224,936 $254 Million
Q4 2019 Feb 14, 2020	SELL	$49.86 - $58.26 $5.75 Million - $6.71 Million	-115,224 Reduced 2.55%	4,404,600 $255 Million
Q3 2019 Nov 13, 2019	BUY	$47.54 - $53.43 $1.66 Million - $1.86 Million	34,846 Added 0.78%	4,519,824 $234 Million
Q2 2019 Aug 09, 2019	BUY	$46.79 - $52.47 $642,239 - $720,203	13,726 Added 0.31%	4,484,978 $229 Million
Q1 2019 May 14, 2019	BUY	$46.36 - $52.63 $507,271 - $575,877	10,942 Added 0.25%	4,471,252 $234 Million
Q4 2018 Feb 13, 2019	BUY	$41.54 - $47.25 $81,626 - $92,846	1,965 Added 0.04%	4,460,310 $205 Million
Q3 2018 Nov 14, 2018	SELL	$46.76 - $51.24 $1.81 Million - $1.98 Million	-38,615 Reduced 0.86%	4,458,345 $210 Million
Q2 2018 Aug 14, 2018	SELL	$44.29 - $50.42 $6.4 Million - $7.29 Million	-144,498 Reduced 3.11%	4,496,960 $207 Million
Q1 2018 May 10, 2018	SELL	$48.49 - $58.14 $4.6 Million - $5.52 Million	-94,944 Reduced 2.0%	4,641,458 $229 Million
Q4 2017 Feb 13, 2018	SELL	$47.53 - $53.73 $14.1 Million - $16 Million	-297,677 Reduced 5.91%	4,736,402 $254 Million
Q3 2017 Nov 08, 2017	BUY	$41.15 - $49.22 $207 Million - $248 Million	5,034,079	5,034,079 $242 Million

Others Institutions Holding NVO

# of Institutions

1,851

Shares Held

309M

Call Options Held

5.29M

Put Options Held

4.93M

View Full List

About NOVO NORDISK A S

Ticker NVO
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 2,257,289,984
Market Cap $305B
Description
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabeti...

More about NVO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fayez Sarofim & CO, based on Form 13F filings with the SEC.

News

Stay updated on Fayez Sarofim & CO with notifications on news.

Account